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Abstract
Background: A variety of pain conditions have been found to be associated with depressed mood in clinical studies.
Depression-like behaviors have also been described in animal models of persistent or chronic pain. In rodent chronic
neuropathic pain models, elevated levels of GluA1 subunits of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors in the nucleus accumbens (NAc) have been found to inhibit depressive symptoms. However, the
effect of reversible post-surgical pain or inflammatory pain on affective behaviors such as depression has not been well
characterized in animal models. Neither is it known what time frame is required to elicit AMPA receptor subunit
changes in the NAc in various pain conditions.
Results: In this study, we compared behavioral and biochemical changes in three pain models: the paw incision (PI)
model for post-incisional pain, the Complete Freund’s Adjuvant (CFA) model for persistent but reversible inflammatory
pain, and the spared nerve injury (SNI) model for chronic postoperative neuropathic pain. In all three models,
rats developed depressive symptoms that were concurrent with the presentation of sensory allodynia. GluA1
levels at the synapses of the NAc, however, differed in these three models. The level of GluA1 subunits of
AMPA-type receptors at NAc synapses was not altered in the PI model. GluA1 levels were elevated in the
CFA model after a period (7 d) of persistent pain, leading to the formation of GluA2-lacking AMPA receptors. As
pain symptoms began to resolve, however, GluA1 levels returned to baseline. Meanwhile, in the SNI model, in which
pain persisted beyond 14 days, GluA1 levels began to rise after pain became persistent and remained elevated. In
addition, we found that blocking GluA2-lacking AMPA receptors in the NAc further decreased the depressive
symptoms only in persistent pain models.
Conclusion: Our study shows that while both short-term and persistent pain can trigger depression-like behaviors,
GluA1 upregulation in the NAc likely represents a unique adaptive response to minimize depressive symptoms in
persistent pain states.
Background
Depression affects up to 100 % of chronic pain patients,
and numerous studies suggest that depressed mood ac-
companies postoperative pain as well [1–7]. Depression
leads to additional emotional and cognitive deficits, fur-
ther impairing recovery and rehabilitation from surgery
or injury [8]. While there is evidence that depression al-
ters the threshold of pain, only a limited number of
studies have examined whether depression is an integral
affective component of the pain experience [9–14]. Pain
and depression often co-exist in patients, making it diffi-
cult to distinguish a causal relationship. Animal studies
provide an opportunity to detect the causal relationship
between pain and depressive symptoms and to dissect
the molecular mechanisms that regulate this relation-
ship. In rodents, depression-like behaviors can be
assessed using the classic sucrose preference test (SPT)
[15], and a number of studies have begun to demon-
strate that chronic pain in rats leads to depression-like
behaviors [16–20].
Imaging studies have shown that pain activates the nu-
cleus accumbens (NAc) [21–23], a brain region well-
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known to mediate reward-driven behaviors [24, 25]. At the
circuit level, the NAc forms reciprocal projections with the
amygdala, prefrontal cortex (PFC) and hippocampus –
critical regions for pain and depression [18, 20, 26–29].
Recently, neurotrophic, metabolic, transcriptional and epi-
genetic signaling mechanisms in the NAc have been dis-
covered to regulate depressive behaviors in animal
studies [30–34]. Given its established role in depression
and its circuit connection to other affective pain cen-
ters, the NAc may be expected to contribute to the
regulation of pain-induced depression. Molecular changes
within the NAc, however, are still not well-defined in pain
states.
A previous study shows that the trafficking of GluA1
subunits of the α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptor in the NAc represents a
critical synaptic mechanism in the regulation of chronic
neuropathic pain [17]. AMPA receptors, which are the
main excitatory postsynaptic receptors for glutamate, are
comprised of four distinct subunits, GluA1-4, and subunit
composition is crucial to receptor function. Changes in
GluA1 subunits at the synapses, specifically, have been
shown to strongly regulate depression-like behaviors in a
number of animal models [32, 35–39]. GluA1 and 2 sub-
units are the predominant subunit types in the NAc.
Chronic neuropathic pain has been shown to increase
GluA1 levels at the NAc synapses, without a concurrent
change in GluA2 levels. This selective increase in GluA1
levels leads to the formation of GluA2-lacking AMPA re-
ceptors [40–42]. Transmission through these GluA2-
lacking AMPA receptors in the NAc, in turn, reduces the
depressive symptoms of pain [17]. Thus, AMPA receptor
trafficking and signaling dynamics represent a powerful
endogenous mechanism to help maintain normal he-
donic response in the context of neuropathic pain,
likely as an adaptive response to pain. It is not clear,
however, whether GluA1 upregulation in the NAc rep-
resents a unique synaptic adaptation to neuropathic
pain. Neither is it known if this form of synaptic plasti-
city is also found with transient or reversible pain con-
ditions. The answer to these questions can enhance our
understanding of chronic pain at the synaptic and cir-
cuit level in the brain.
In the current study, we compare sensory and affective
symptoms of three different pain models in rats. We use
the paw incision (PI) model to mimic short-term post-
incisional pain [43]. We use the Complete Freund’s Ad-
juvant (CFA) model to mimic persistent but reversible
inflammatory pain, and the spared nerve injury (SNI)
model to mimic chronic or long-lasting neuropathic
pain. We find that in all three pain models, depression-
like behaviors develop concurrently with sensory allody-
nia, suggesting that depressive and sensory symptoms of
pain co-exist. GluA1 upregulation, however, is only found
with persistent or chronic pain, as it is not found in the PI
model. Furthermore, as pain begins to resolve in the CFA
model, GluA1 level also returns to baseline. In contrast, in
the SNI model, where pain persists for at least 14 days,
GluA1 level remains elevated. In addition, a blockade of
GluA2-lacking AMPA receptors in the NAc has no effect
on the pain behaviors in the PI model, but it further de-
creases the depressive symptoms in the CFA and SNI
models. These results suggest that GluA1 elevation repre-
sents a unique dynamic synaptic adaptation to the persist-
ence of pain. This dynamic response provides insight into
the role the brain’s reward system plays in chronic pain,
and it can potentially serve as a useful molecular marker
for the chronicity of pain.
Results
Post-incisional pain causes depression-like behaviors in
rats
We used the Brennan (PI) model to mimic post-
incisional pain in rats [43, 44]. Here, we incised the right
hind paw and measured mechanical allodynia in this
paw over the next seven days. As reported previously,
mechanical allodynia, which indicated the sensory com-
ponent of pain, developed quickly after paw incision
(<6 h) (Fig. 1a, p < 0.0001) [43, 44]. Mechanical allodynia
lasted two days, and as described previously, these sen-
sory pain symptoms resolved by the 7th day post-incision
(Fig. 1a). In contrast, control rats that had only under-
gone isofluorane anesthesia treatment without surgical
incision did not display any mechanical allodynia.
Next, we measured sucrose preference in rats that ex-
perienced PI vs. control rats. Sucrose preference test
(SPT) is a classic test for depression-like behaviors in ro-
dents [15]. Specifically, a decrease in rats’ preference for
sucrose, a natural reward, indicates anhedonia, a hall-
mark feature for depression that is pathognomonic in
human patients. Compared to control rats, rats in the PI
group demonstrated a significant decrease in sucrose
preference on day 1 and 2 after incision (Fig. 1b, p < 0.05).
This level of decrease in sucrose preference is very similar
to what has been previously reported for chronic neuro-
pathic pain models [17]. This decrease in sucrose prefer-
ence was not due to changes in the PI-treated rats’ ability
to drink, as there was no statistically significant difference
between the control and PI groups in the volume of total
fluid consumption (Fig. 1c, p > 0.05). The PI group con-
sumed a smaller volume of sucrose solution than control,
and these rats drank more water during the test (Fig. 1d, e,
p > 0.05). These changes were not statistically significant.
Together, however, decreased sucrose consumption and
increased water consumption result in a statistically sig-
nificant decrease in sucrose preference in the PI group,
suggesting the symptom of pain-induced depression [15].
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From a kinetic standpoint, sucrose preference was de-
pressed for two days and returned to control levels 7 days
after PI (Fig. 1b). This time-course of decline and return
to normal sucrose preference is remarkably consistent
with the development and subsequent resolution of
mechanical allodynia (Fig. 1a). These results suggest that
post-incisional pain can trigger short-term reversible
depression-like behaviors.
Persistent inflammatory pain causes depression-like
behaviors in rats
We used the CFA model to study the time course of
presentation of depressive symptoms in an inflammatory
pain model. We injected 100 μl CFA into the rat’s right
hind paw, and this resulted in localized inflammation
and pain. Rats developed mechanical allodynia post-CFA
injection, whereas control rats receiving saline injection
showed no sensory allodynic changes (Fig. 2a, p < 0.01).
Furthermore, at the dose of CFA in this study, inflam-
mation and associated sensory nociceptive symptoms
began to resolve 14 days after a single injection, as indi-
cated by a return of mechanical sensitivity towards nor-
mal control threshold (Fig. 2a).
We assessed depressive symptoms of inflammatory pain
using the SPT. Compared to control rats, the CFA group
demonstrated a significantly decreased sucrose preference
on day 1, 2 and 7 after CFA injections (Fig. 2b, p < 0.05).
Again, total fluid consumption was not different in these
two groups of rats (Fig. 2c, p > 0.05), suggesting that the dif-
ference in sucrose preference was not due to altered ability
of CFA-treated rats to consume fluid. Instead, this differ-
ence was due to the fact that the CFA group consumed less
A B
C D E
Fig. 1 Paw incision (PI) leads to short-term pain and depression-like behaviors. a PI-treated rats developed mechanical allodynia up to
two days after surgery, compared with control rats that underwent isofluorane treatment without surgery. Two-way ANOVA with Bonferroni post-test,
n = 6, ****p < 0.0001. On day 7 after PI, there was no statistical difference in the withdrawal threshold between the PI and control groups. b PI decreased
sucrose preference on the SPT on day 1 and 2 after the procedure, Two-way ANOVA with Bonferroni post-test, n= 10, *P< 0.05. c PI caused no changes in
total fluid consumption on the SPT 1 day after surgery. Student’s t-test, n= 10, p> 0.05. d PI caused a decrease trend of sucrose consumption on the SPT
1 day after surgery. Student’s t-test, n= 10, p> 0.05. e PI caused an increased trend of water consumption on the SPT 1 day after surgery. Student’s t-test,
n = 10, p > 0.05. Error bars show mean and SEM
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volume of sucrose solution than control (Fig. 2d, p > 0.05),
and they drank statistically more water during the test
(Fig. 2e, p < 0.05).
14 days after CFA injection, sensory pain symptoms
began to resolve, as indicated by a significant increase in
mechanical threshold (Fig. 2a). On the SPT, meanwhile,
the difference in sucrose preference between these two
groups completely disappeared 14 days after CFA admin-
istration (Fig. 2b, p > 0.05). Qualitatively, these results in-
dicate that both sensory and depressive symptoms of pain
begin to resolve after 14 days.
Persistent neuropathic pain causes depression-like
behaviors in rats
Recently, a number of studies have reported depression-like
behaviors in rats with chronic neuropathic pain [16, 18].
Here, we used the SNI model to determine the time course
of development of these depressive symptoms [16]. As
previously reported, rats developed mechanical allodynia as
early as 1 day after the SNI procedure, and this abnormal
sensory hypersensitivity persisted for at least 14 days fol-
lowing SNI (Fig. 3a, p < 0.0001). In contrast, the control
group that underwent sham operation did not show any
sensory hypersensitivity (Fig. 3a).
Next, we measured sucrose preference after sham or
SNI procedures. We found that both sham and SNI-
treated rats showed a decreased preference for sucrose
1 day after surgery (Fig. 3b). In the case of sham-treated
rats, incisional pain from sham surgery likely caused this
short-term decrease in sucrose preference, similar to
what we found with PI-treated rats (Fig. 1b). Sham-
treated rats, however, quickly recovered their normal su-
crose preference starting on postoperative day 2, likely
because these rats began to recover from incisional pain.
In contrast, sucrose preference decreased further in the
SNI group over the next 7–14 days, as neuropathic pain
A B
C D E
Fig. 2 Complete Freund’s Adjuvant (CFA) causes persistent inflammatory pain and depression-like behaviors. a Rats developed mechanical allodynia after
CFA injection, compared with control (saline) injection. Two-way ANOVA with Bonferroni post-test, n= 6–9, **p< 0.01, ****p < 0.0001. b Rats developed
decreased sucrose preference on the SPT on day 1, 2 and 7 after CFA injection. Two-way ANOVA with Bonferroni post-test, n= 6–11, *p < 0.05, **p < 0.01.
c CFA caused no changes in total fluid consumption on the SPT 7 days after injection. Student’s t-test, n= 10–11, p > 0.05. d CFA caused a decreased
trend of sucrose consumption on the SPT 7 days after injection. Student’s t-test, n= 10–11, p > 0.05. e CFA caused increased water consumption on the
SPT 7 days after injection. Student’s t-test, n= 10-11, *p < 0.05. Error bars show mean and SEM
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from nerve injury worsened and became persistent or
chronic (Fig. 3b). As the result, there were significant
differences in sucrose preference on postoperative day 7
and 14 between these the sham and SNI groups (Fig. 3b,
p < 0.05). These differences on SPT were due to de-
creased consumption of sucrose and increased con-
sumption of water by the SNI group (Fig. 3d, e, p < 0.05).
The total fluid consumption was not statistically differ-
ent, however, in these two groups of rats (Fig. 3c).
Post-incisional pain does not increase GluA1 levels at NAc
synapses
Chronic neuropathic pain has been shown to selectively
increase GluA1 levels in the NAc, and this increase con-
tributes to the synaptic incorporation of GluA2-lacking
receptors. Transmission through these GluA2-lacking
receptors in turn reduces the depressive symptoms of
pain [17]. Thus, GluA1 upregulation represents an
important synaptic mechanism in the NAc to regulate
the depressive symptoms of pain. Here we investigated
whether this elevation in synaptic GluA1 levels is also a
feature of reversible post-incisional pain. We used
synaptoneurosome preparations to study AMPA recep-
tor subunits at NAc synapses. Over 90 % of neurons in
the NAc are medium spiny neurons, and synaptoneuro-
some preparations reflect synaptic fractions of these
neurons. GluA1 and GluA2 are the most abundant
AMPA receptor subunit types in the NAc. Thus, we
measured the levels of GluA1 and GluA2 subunits from
synaptoneurosome in the NAc using Western blots at
different time points after PI. Interestingly, there were
no statistically significant changes in the levels of GluA1
and GluA2 subunits between the PI and control groups
1 or 2 days after the onset of pain (Fig. 4a, b, p > 0.05).
To make sure that GluA1 upregulation does not repre-
sent a delayed response after incision, we then measured
A B
C D E
Fig. 3 Spared nerve injury (SNI) causes persistent neuropathic pain and depression-like behaviors. a SNI-operated rats developed persistent mechanical
allodynia after surgery, compared with sham-operated rats. Two-way ANOVA with Bonferroni post-test, n= 4–9, ****p< 0.0001. b SNI-treated rats
developed worse sucrose preference than sham-treated rats on postoperative day 7 and 14. Two-way ANOVA with Bonferroni post-test,
n = 4–10, *p < 0.05, **p < 0.01. c SNI caused no changes in total fluid consumption on the SPT 7 days after surgery. Student’s t-test, n= 9–10, p > 0.05.
d SNI caused decreased sucrose consumption on the SPT 7 days after surgery. Student’s t-test, n = 9–10, *p < 0.05. e SNI caused increased
water consumption on the SPT 7 days after surgery. Student’s t-test, n = 9–10, *p < 0.05. Error bars show mean and SEM
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GluA1 and GluA2 levels 7 days after PI. Again we found
no alterations in GluA1/2 levels (Fig. 4c, p > 0.05). These
results indicate that short-term post-incisional pain (of
less than 7 days duration) does not trigger alterations in
the AMPA receptor composition in the NAc.
Inflammatory pain reversibly increases GluA1 levels at
NAc synapses
To understand if AMPA receptor plasticity in the NAc is
unique to persistent neuropathic pain states, we evaluated
the levels of GluA1 and GluA2 subunits at NAc synapses
in the inflammatory pain (CFA) model. We found that
shortly after the onset of pain (1 and 2 days after CFA in-
jection), the levels of GluA1 and GluA2 were not altered
(Fig. 5a, b, p > 0.05). This finding mirrors the finding from
the PI model, in which post-incisional pain did not change
GluA1/2 levels (Fig. 4a, b). However, 7 days after CFA in-
jection, when pain had become persistent (Fig. 2), the levels
of GluA1 subunits were increased (>30 %) in the CFA
group compared with the control group (Fig. 5c, p < 0.01).
GluA2 subunit levels, in comparison, remained unchanged.
These findings indicate that changes in AMPA receptor
levels are not restricted to neuropathic pain states. We
then measured GluA1/2 levels 14 days after CFA/saline in-
jections to see if this selective increase GluA1 levels at
NAc synapses persisted even when pain had begun to sub-
side in CFA-treated rats (Fig. 2). Interestingly, we found
that at this time point, GluA1 levels also began to return to
control levels (Fig. 5d, p > 0.05). These results suggest that
GluA1 upregulation in the NAc occurs once pain has be-
come persistent (>7 d), but that with the resolution of pain,
GluA1 levels also return to normal.
A selective increase in synaptic level of GluA1 sub-
units, without a change in GluA2, indicates an increase
in the overall number of AMPA receptors at synapses.
Furthermore, this selective increase in GluA1 levels sug-
gests the new formation of GluA2-lacking AMPA recep-
tors, which are known to augment synaptic transmission
due to higher conductance and the ability to trigger
intracellular calcium signaling [40–42]. To confirm the
formation of GluA2-lacking AMPA receptors in the per-
sistent inflammatory pain state, we performed whole-cell
patch clamp recordings from neurons in brain slices of
the NAc 7 days after CFA or saline injection (Fig. 6). Ex-
citatory postsynaptic currents (EPSCs) conducted by
GluA2-lacking AMPA receptors display characteristic
inward rectification due to channel block at depolarized
potentials by endogenous polyamines [41]. We identified
MSNs visually in the NAc core region, and recorded
evoked EPSCs from these neurons (Fig. 6). Indeed, EPSCs
from neurons in CFA-treated animals displayed an inward
rectification, as indicated by nonlinearity in the current–
voltage (I/V) relationship (Fig. 6a, c). This inward rectifi-
cation was minimally expressed, however, in neurons from
saline-treated rats (Fig. 6b, c). We then calculated the rec-
tification index (RI) using I/V relationships for saline and
A B C
Fig. 4 Paw incision does not cause an alteration in GluA1 and GluA2 levels at the synapses of the NAc. a Levels of GluA1 and GluA2 subunits in
synaptoneurosome preparations from the NAc did not alter 1 day after PI. Two-way ANOVA with Bonferroni post-test, n= 6 (GluA1), p> 0.05; n= 6 (GluA2),
p> 0.05. b Synaptic levels of GluA1 and GluA2 subunits did not alter 2 days after PI. Two-way ANOVA with Bonferroni post-test, n = 6 (GluA1), p > 0.05;
n = 6 (GluA2), p > 0.05. c Synaptic levels of GluA1 and GluA2 subunits did not alter 7 days after PI. Two-way ANOVA with Bonferroni post-test, n = 6
(GluA1), p > 0.05; n = 6 (GluA2), p > 0.05. Data were normalized to values in the control group. Error bars show mean and SEM
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CFA-treated animals [45]. When we compared the RIs for
these two groups, we found a substantial difference (>50
% increase in the CFA group; p < 0.01, Fig. 6d). These elec-
trophysiological data confirm the findings from our bio-
chemical analysis and further indicate that persistent
inflammatory pain leads to the formation of GluA2-
lacking AMPA receptor currents in the NAc.
Neuropathic pain causes persistent increases in GluA1
levels at NAc synapses
Chronic neuropathic pain has been shown to increase
GluA1 expression and cause the formation of GluA2-
lacking AMPA receptors at NAc synapses [17]. The time
course of this GluA1 increase, however, has not been
established. Our data on inflammatory pain suggests that
A B
C D
Fig. 5 Persistent inflammatory pain causes a reversible increase in GluA1 levels at NAc synapses. a Levels of GluA1 and GluA2 subunits in
synaptoneurosome preparations from the NAc did not alter 1 day after CFA injections. Two-way ANOVA with Bonferroni post-test, n = 5
(GluA1), p > 0.05; n = 6 (GluA2), p > 0.05. b Synaptic levels of GluA1 and GluA2 subunits in the NAc did not alter 2 days after CFA injections. Two-way
ANOVA with Bonferroni post-test, n = 4–6 (GluA1), p > 0.05; n = 4–6 (GluA2), p > 0.05. c 7 days after CFA administration, levels of GluA1 were
selectively increased at NAc synapses, whereas GluA2 levels were not altered. Two-way ANOVA with Bonferroni post-test, n = 8 (GluA1), **p < 0.01; n = 8
(GluA2), p > 0.05. d 14 days after CFA injection, GluA1 levels returned to control levels at NAc synapses, whereas GluA2 levels remained unchanged.
Two-way ANOVA with Bonferroni post-test, n = 7–8 (GluA1), p > 0.05; n= 7–8 (GluA2), p > 0.05. Data were normalized to values in the control group.
Error bars show mean and SEM
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GluA1 upregulation is a response to persistent pain.
Thus, we hypothesized that GluA1 levels at NAc synap-
ses would remain elevated as long as pain persisted. To
test this hypothesis, we turned to the SNI model, which
is known to cause pain lasting up to six months [16, 46].
We measured the levels of GluA1 and GluA2 subunits
from synaptoneurosome preparations of NAc neurons 1,
2, 7 and 14 days after SNI or sham surgery. Concordant
with our findings in PI and CFA models, we found no
changes in the levels of GluA1 and GluA2 subunits be-
tween SNI and sham rats 1 or 2 days after surgery
(Fig. 7a, b, p > 0.05). Compatible with what we found in
the CFA model, however, GluA1 levels began to increase
7 days after SNI (Fig. 7c, p < 0.05). Furthermore, the
level of increase (30 % from control levels) was quantita-
tively similar in CFA and SNI models at this time point.
Meanwhile, as pain persisted 14 days after SNI (Fig. 3),
GluA1 subunit levels continued to increase (>80 %,
Fig. 7d, p < 0.05). GluA2 levels, in contrast, remained un-
altered (Fig. 7a-d). These data support our hypothesis
that GluA1 upreguation at NAc synapses represents an
adaptive response to persistent pain. It further indicates
that this form of synaptic plasticity occurs regardless of
the peripheral source of pain.
Persistent pain increases the trafficking of GluA1 to NAc
synapses
A common mechanism for increased AMPA receptor
subunit expression at the synapse is increased exocytotic
trafficking [47, 48]. To assess the role of trafficking, we ex-
amined the phosphorylation of GluA1 Ser845, which has
previously been shown to be a critical step for the target-
ing of GluA1 to the synaptic surface [49]. Here, we found
that the level of phospho-Ser845 in the synaptoneuro-
somes of NAc was increased by approximately the same
amount as GluA1 subunit levels 7 days after the onset of
pain in both CFA and SNI models (Fig. 8a, b, p < 0.05).
These results suggest that this trafficking mechanism is
conserved in the persistent pain state regardless of the
peripheral cause of pain. Hence most likely phosphoryl-
ation at Ser845 has contributed to the trafficking of GluA1
subunits to the NAc synapses in persistent pain states.
GluA2-lacking receptors in the NAc regulates depression-
like behaviors associated with persistent pain
Most AMPA receptors contain GluA2 subunits. A select-
ive increase in the synaptic level of GluA1 subunits with-
out a concurrent change in the GluA2 level, however, has
been shown to lead to the formation of GluA1 homomers,
which are GluA2-lacking AMPA receptors [17, 40–42].
GluA2-lacking receptors display unique biophysical prop-
erties including Ca2+ permeability and high single unit
conductance, and these receptors have been shown to
regulate a host of behaviors [40–42], including the relief
of depressive symptoms of persistent neuropathic pain in
the SNI model [17].
In order to understand the roles of GluA1 subunits in
PI and CFA models, we injected 1-naphthyl acetyl sperm-
ine/N-acetyl-spermine (Naspm), a highly selective blocker
of GluA2-lacking AMPA receptors, into the NAc to exam-
ine the effect of blocking these receptors on sensory and
depressive features of pain (Fig. 9a, b). In the PI model,
our biochemical assays showed no increases in GluA1
levels, suggesting that no new GluA2-lacking receptors
were formed shortly after surgical incision. Thus, it is not
surprising that the infusion of Naspm, which selectively
blocks GluA2-lacking receptors but not GluA2-containing
receptors, did not have a significant effect on pain behav-
iors in this model (Fig. 9c-e).
Next, we examined the effect of Naspm on behavioral
responses to persistent inflammatory pain. Our biochem-
ical data suggest that 7 days after the onset of pain, GluA1
levels are selectively increased, allowing the formation of
GluA2-lacking receptors at the NAc synapse (Figs. 5c, 6).
We found that Naspm infusion into the NAc did not alter
mechanical hypersensitivity 7 days after CFA injection
(Fig. 9g, p > 0.05), suggesting that increased GluA1 sub-
units do not play a dominant role in regulating the
A C D E
B
Fig. 6 Persistent inflammatory pain causes the formation of GluA2-lacking AMPA receptors in the NAc. a-c Neurons in the NAc from rats that received
CFA injection showed decreased EPSCs at depolarized voltages, compared with neurons from rats that received saline treatment. a, b Representative
traces; c Normalized cumulative current–voltage relationship. d EPSCs from CFA-treated rats showed increased rectification index. Student’s t
test, n = 10-12 neurons from 3 rats, **p < 0.01. e Schematic of the NAc showing EP recording sites in red circles. Recordings were done 7 days after
either CFA or saline injection. Error bars show mean and SEM
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sensory transmission of the pain signal. However, glutam-
ate signaling is known to play an important role in depres-
sion [50–52], and increased transmission through AMPA
receptors have been shown to confer antidepressant ef-
fects [16, 53–55]. Therefore, we next examined the effect
of blocking GluA2-lacking AMPA receptors in the NAc
on depression-like behaviors induced by persistent inflam-
matory pain using the SPT. Sucrose preference was
decreased in CFA-treated rats compared with saline-
treated rats (Fig. 2b). When we measured sucrose prefer-
ence in the presence of Naspm treatment (vs. saline) in
CFA-treated rats, however, we found that it was substan-
tially further reduced (Fig. 9h, p < 0.05). Thus, blocking
GluA2-lacking receptors in the NAc worsened anhedonia,
a key feature of depression-like behaviors in CFA-treated
rats. These results in the inflammatory pain model
A B
C D
Fig. 7 Chronic neuropathic pain causes a continued increase in GluA1 levels at NAc synapses. a Levels of GluA1 and GluA2 subunits in
synaptoneurosome preparations from the NAc did not alter 1 day after SNI. Two-way ANOVA with Bonferroni post-test, n = 6 (GluA1), p > 0.05; n = 6
(GluA2), p > 0.05. b Synaptic levels of GluA1 and GluA2 subunits in the NAc did not alter 2 days after SNI. Two-way ANOVA with Bonferroni post-test,
n = 6 (GluA1), p > 0.05; n = 6 (GluA2), p > 0.05. c 7 days after SNI, levels of GluA1 were selectively increased at NAc synapses, whereas GluA2
levels were not altered. Two-way ANOVA with Bonferroni post-test, n = 8–9 (GluA1), *p < 0.05; n = 5–6 (GluA2), p > 0.05. d 14 days after SNI,
GluA1 levels continued to be elevated at NAc synapses, whereas GluA2 levels were unchanged. Two-way ANOVA with Bonferroni post-test,
n = 5–7 (GluA1), *p < 0.05; n = 6 (GluA2), p > 0.05. Data were normalized to values in the control group. Error bars show mean and SEM
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have two important implications. First, they confirm our
biochemical and electrophysiological results (Figs. 5c and
6) and indicate that GluA2-lacking AMPA receptors are
formed in response to persistent pain. Second, these re-
sults are similar to previously reported results in the SNI
model [17], and together, these findings suggest that, in
vivo, GluA1 subunits are trafficked to the NAc synapse to
provide protection against depressive symptoms, possibly
as an adaptive mechanism to persistent pain, regardless of
the peripheral etiology of pain.
Discussion
Pain is well-known to cause depressed mood [5–7]. The
causal relationship between pain and depression, how-
ever, has not been completely established. In this study,
we have found that in three different animal pain
models, pain can cause depression-like behaviors in a
time course that is compatible with the development of
sensory allodynia. More importantly, we have found that
GluA1 subunits of the AMPA receptors are selectively
increased at the synapses of NAc only after pain has be-
come persistent, and that increased GluA1 levels func-
tion to relieve depressive symptoms of pain.
Previous studies have shown that chronic neuropathic
pain and inflammatory pain both cause depression-like
behaviors [16–20], but this is the first report that post-
incisional pain, which presents a comparably shorter
duration of pain, also causes a similar depressive pheno-
type. Interestingly, the time course of the development
of depressive symptoms closely mirrors that of sen-
sory allodynia in the PI model. In this model, anhe-
donic symptoms developed and resolved at the same
time point when allodynic symptoms developed and
resolved.
In the persistent inflammatory pain (CFA) model, an-
hedonia also developed concurrently with allodynia. In
this pain model, anhedonic symptoms resolved after
7 days, when allodynic symptoms also began to resolve.
Qualitatively, these results indicate that both sensory
and depressive symptoms of pain resolve after a period
of time. Quantitatively, however, these data suggest that
the affective symptoms of pain resolve more completely
than the sensory symptoms of pain early in the process
of recovery from peripheral inflammatory insult. Such
findings are in fact compatible with what has been re-
ported in the clinical literature on acute and chronic
pain, where affective indices for pain have been sug-
gested to normalize earlier than reports of sensory pain
scores [1, 6, 56, 57].
In the chronic neuropathic pain (SNI) model, due to
the initial incisional pain caused by sham surgery, the
sham group also developed reversible anhedonic symp-
toms. Therefore, the difference in sucrose preference be-
tween the SNI and sham groups was not pronounced for
the first two days. After two days, however, sham-treated
rats recovered their normal hedonic response, just like
PI-treated rats. SNI-treated rats, in contrast, continued
to display anhedonic symptoms.
A B
Fig. 8 Persistent inflammatory pain and neuropathic pain increase pSer845-GluA1 levels at NAc synapse. a 7 days post injection, levels of pSer845-GluA1
increased in synaptoneurosome preparations from the NAc in CFA-treated rats. Student’s t-test, n= 6 (Saline); n= 6 (CFA), *p< 0.05. b 7 days post-surgery,
levels of pSer845-GluA1 increased at NAc synapses in SNI-treated rats. Student’s t-test, n= 7 (Sham); n= 9 (SNI), *p< 0.05. Data were normalized to values in
the control group. Error bars show mean and SEM
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Overall, results from these three distinct rat models
suggest that depressive symptoms consistently accom-
pany sensory symptoms of pain. These results indicate
that depression is caused by pain, and that depressive
symptoms are an integral component of the pain experi-
ence. There is a growing interest in understanding the
mechanisms regulating the affective component of pain,
including depressed mood [19, 58, 59]. Our results here
validate the use of rat models for the study of depressive
pain symptoms.
An alternative explanation for our data is that depres-
sion and pain developed independently. However, this is
unlikely in our study. In the current study, the time
course of depression-like behaviors as shown by anhedo-
nia on the SPT closely mirrors the time course of sen-
sory allodynia in all three pain models. As soon as
allodynia begins to diminish, signaling the resolution of
post-incisional or inflammatory pain, the hedonic re-
sponse of rats also returns to normal. Thus, the most
likely explanation of our data is that pain directly causes
depression-like behaviors. This explanation is also com-
patible with clinical observations [5, 7].
Prior imaging studies have identified the NAc as a
brain region that undergoes changes in morphology
and connectivity in response to both acute and chronic
pain [21–23, 60]. The changes in the NAc that occur at the
molecular and synaptic levels, however, are less well char-
acterized in the context of pain. Chronic neuropathic pain
has been shown to selectively increase GluA1 subunit levels
at the NAc synapses, leading to the formation of GluA2-
lacking AMPA receptors [17]. An important contribution
in the current study is to define the exact time course of
this crucial synaptic event. In the broader context, our





Fig. 9 GluA2-lacking receptors in the NAc regulate depression-like behaviors induced by persistent inflammatory pain but not short-term postoperative
pain. a Schematic showing Naspm infusion. b Placement of injectors depicted by red circles. c Timeline for experiments in PI-treated rats.
d, Naspm infusion into the NAc core did not change mechanical hypersensitivity in PI-treated rats (1 day after procedure). Student’s t-test,
n = 6 (Saline); n = 7 (Naspm), p > 0.05. e Naspm did not change sucrose preference in PI-treated rats. Student’s t-test, n = 8 (Saline); n = 8 (Naspm),
p > 0.05. f Timeline for experiments in CFA-treated rats. g Naspm infusion into the NAc did not change mechanical hypersensitivity in CFA-treated rats
(7 days after injection). Student’s t-test, n= 7 (Saline); n= 7 (Naspm), p> 0.05. h Naspm in the NAc reduced sucrose preference in CFA-treated rats. Student’s
t-test, n= 9 (Saline); n= 8 (Naspm), *p< 0.05. Error bars show mean and SEM
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studies demonstrating the roles, within the NAc, of
opioid signaling and dopamine signaling in regulating
descending inhibition, stress-induced hyperalgesia, and
negative reinforcement from pain-relief [61–64].
The synaptic incorporation of GluA1 subunits re-
quires a series of highly regulated signaling steps in-
volving sequential phosphorylation at a number of
key residues [49, 65–68]. Thus, the synaptic incorpor-
ation of these receptors tends to be found under unique be-
havioral conditions such as repeated consumption of
cocaine or sucrose, prolonged cocaine withdrawal, fear con-
ditioning, and stress [32, 39, 45, 69–72]. Chronic neuro-
pathic pain has been shown to selectively increase GluA1
subunit levels at the NAc synapses, leading to the formation
of GluA2-lacking AMPA receptors [17]. Our results here
suggest that this form of synaptic plasticity is not seen in
acute pain and is thus specific to persistent or chronic pain
states. Such synaptic plasticity, however, is not unique to
neuropathic pain, as persistent inflammatory pain can also
cause GluA1 upregulation. Furthermore, our data suggests
that phosphorylation of Ser845 may be an important mech-
anism in the trafficking of GluA1 to the NAc synapse in
the inflammatory pain model, similar to previous findings
demonstrating the involvement of Ser845 phosphorylation
in the synaptic targeting of GluA1 in the SNI model [17].
Thus, phosphorylation of Ser845 plays an important role in
delivering GluA1 to the NAc synapses in the presence of
persistent pain.
Our results in CFA and SNI models suggest that at least
7 days of persistent pain are required to increase GluA1
AMPA receptor subunits in the NAc. Interestingly, this
time frame is almost identical to the amount of time re-
quired to increase GluA1 subunits in the NAc in the con-
text of repeated consumption of a natural reward [70].
Natural rewards and pain represent opposite valence in
the reward-aversion valuation spectrum. Indeed, GluA1
upregulation has been reported in a number of studies on
rewards [45, 70, 73]. Interpreted in this context, our re-
sults suggest that rewards and pain provide similar stimuli
to trigger AMPA receptor plasticity in the NAc. There is
increasing evidence that the NAc codes both the salience
and the valence of a stimulus [74–77]. Thus, it is not sur-
prising that similar synaptic changes occur in response to
both pain and rewards.
The comparison between the CFA and SNI models re-
veals that GluA1 upregulation is not permanent. Pain in
the CFA model begins to resolve after 14 days. GluA1
levels at the synapse also return to normal at the same
time. The level of GluA1 subunits at the NAc synapse
remains elevated, however, in the SNI model, because
pain also remains persistent 14 days after SNI. This
comparison suggests that AMPA receptor signaling not
only codes the intensity of an aversive stimulus, but it
also codes the duration of this stimulus.
A selective increase in GluA1 subunits without alter-
ations in GluA2 levels leads to the synaptic incorporation
of GluA2-lacking AMPA receptors [40–42]. Delayed GluA1
upregulation has been described in the NAc with repeated
consumption of natural rewards or drugs of addiction [70,
78], similar to AMPA receptor changes identified with pro-
longed disturbances of sensory systems [79]. In these
models, homeostatic plasticity has been posited as a poten-
tial mechanism for the formation of GluA2-lacking recep-
tors to regulate behavior. The length of time required to
increase GluA1 levels in persistent pain states found in our
study is compatible with the time course found in these
other behavioral models. This similarity raises the intri-
guing possibility that the synaptic modification observed in
persistent pain states may also represent a form of homeo-
static plasticity in the reward system.
Our pharmacological experiments suggest that increased
GluA1 levels in the NAc constrain the depressive symp-
toms of persistent inflammatory pain. Previous studies have
identified a similar role for GluA1 in neuropathic pain
states [17]. Thus, AMPA receptors play a key role in the
regulation of depressive symptoms of pain regardless of the
etiology of pain. In a broader sense, these results suggest
that glutamate signaling in the NAc may be an important
mechanism that links persistent pain with depression. The
NAc receives glutamatergic inputs from the PFC, hippo-
campus, amygdala, and the thalamus [80]. Glutamate sig-
naling in the PFC, amygdala and hippocampus has been
studied in the regulation of depression [26–28, 35–37].
Interestingly, altered synaptic activities within these regions
have also been demonstrated to regulate cognitive and
affective responses to pain [81–85]. Thus, a glutamatergic
circuit that involves the PFC, amygdala, hippocampus and
NAc may form an important basis for understanding the
connection between pain and depression. Future studies to
further define the role of AMPA receptor signaling within
these interconnected regions will likely result in the precise
mapping of an affective pain circuit.
Conclusion
Our study shows that in rats, post-incisional, inflammatory
as well as neuropathic pain all can cause depression-like
behaviors. However, GluA1 upregulation at the synapses of
NAc signals an adaptive response only to persistent pain.
Thus, AMPA receptor trafficking dynamics in the brain’s
reward system plays an important role in the regulation of
chronic pain, and GluA1 levels in the NAc can additionally
serve as a molecular marker for the chronicity of pain.
Materials and methods
Animals
All procedures in this study were approved by the New
York University School of Medicine Institutional Animal
Care and Use Committee (IACUC) as consistent with
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the National Institute of Health (NIH) Guide for the Care
and Use of Laboratory Animals (publication number 85–
23) to ensure minimal animal use and discomfort. Male
Sprague–Dawley rats were purchased from Taconic Farms,
Albany, NY and kept at Mispro Biotech Services Facility in
Alexandria Center for Life Science, with controlled humid-
ity, room temperature, and 12-h (6:00 AM to 6:00 PM)
light–dark cycle. Food and water were available ad libitum.
Animals arrived to the animal facility at 250 to 300 g and
were given on average 7 days to adjust to the new environ-
ment prior to the onset of any experiments.
Animal surgeries and procedures
Paw Incisional (PI) surgery
The paw incisional surgery was performed as previously
described [43], with a few minor modifications. Briefly, rats
were anaesthetized with Isoflurane anesthesia (1.5–2 %),
and the plantar surface of the right hind paw was sterilized
and prepared. A 1.5 cm longitudinal incision was cut with
a number 10 scalpel, through skin and fascia of the right
plantar aspect of the paw. The incision started 0.5 cm from
the proximal end of the heel and extended to the middle
of the paw. The plantaris muscle was elevated and incised
longitudinally. Gentle pressure was applied in order to
cease bleeding and the wound was opposed with three sin-
gle sutures using 5–0 nylon. The animals were allowed to
recover in their home cages. Control rats only received
Isoflurane anesthesia.
Complete Freund’s Adjuvant (CFA) administration
To produce inflammatory pain, CFA (mycobacterium tu-
berculosis, Sigma-Aldrich [St. Louis, MO], 0.1 ml) was
suspended in an oil-saline (1:1) emulsion and injected sub-
cutaneously into the plantar aspect of the hind paw. Con-
trol rats received an equal volume of saline injection.
Spared Nerve Injury (SNI) surgery
The spared nerve injury (SNI) surgery has been previously
described in detail [46]. Briefly, under Isoflurane anesthesia
(1.5–2 %), the skin on the lateral surface of the right thigh
of the rat was incised and the biceps femoris muscle was
dissected in order to expose three branches of the sciatic
nerve: sural, common peroneal, and tibial. The common
peroneal and tibial nerves were tied with non-absorbent 5.0
silk sutures at the point of trifurcation. The nerves were
then cut distal to the knot, and about 3 to 5 mm of the dis-
tal ends were removed. In sham surgeries (control), the
nerves mentioned above were dissected but not cut. Muscle
and skin layers were then sutured closed in distinct layers.
Cannula implantation and intracranial injections
For cannula implantation, as described previously [86],
rats were anesthetized with isofluorane (1.5–2 %). Rats
were stereotaxically implanted with two 26-gauge guide
cannulas (PlasticsOne, Roanoke, VA) bilaterally in the
NAc core with coordinates: 1.6 mm anterior to bregma;
2.9 mm lateral to the sagittal suture, tips angled 8° toward
the midline, 5.6 mm ventral to skull surface. Cannulas
were held in place by dental acrylic and patency was main-
tained with occlusion stylets. For intracranial injections,
solutions were loaded into two 30 cm lengths of PE-50
tubing attached at one end to 10-μl Hamilton syringes
filled with distilled water and at the other end to 33-gauge
injector cannula, which extended 2.0 mm beyond the im-
planted guides. Injection of solution then delivered bilat-
erally 0.5 ul of injection volume over a period of 100 s.
Injector cannulas were kept in place for another 60 s prior
to removal from guides to allow diffusion of solution into
the brain. Following the removal of injector cannulas from
cannula guides, stylets were replaced, and animals were
subject for behavior tests. Behavior tests were done
15 min after intracranial injections. Following animal sac-
rifice, cryogenic brain sections were collected with thick-
ness of 20 um using Microm HM525 Cryostat and
analyzed for cannula localization with histological stain-
ing; animals with improper cannula placements were ex-
cluded from the study.
Drugs
1-naphthyl acetyl spermine/N-acetyl-spermine (Naspm)
was purchased from Sigma. Naspm was resuspended in
saline to a concentration of 80 ug/ul. We injected 0.5 ul in
each side. Intracranial injections were given at least 7 days
after cannula implantation and were followed by behav-
ioral tests. Equal volume of saline was injected as control.
Animal Behavioral Tests
Mechanical hypersensitivity test
A traditional Dixon up-down method with von Frey fila-
ments was used to measure mechanical hypersensitivity
as described previously [16, 87, 88]. In brief, rats were
individually placed into plexiglass chambers over a mesh
table and acclimated for 20 min before the onset of
examination. Beginning with 2.55 g, von Frey filaments
in a set with logarithmically incremental stiffness (0.45,
0.75, 1.20, 2.55, 4.40, 6.10, 10.50, 15.10 g) were applied
vertically to the plantar surface of the right paw, adjacent
to the wound of rats after PI. For SNI and sham group,
von Frey filaments were applied to the lateral 1/3 of
right paws (in the distribution of the sural nerve) of rats
after SNI or sham surgery. Similar tests were done on
CFA- or saline-treated rats. 50 % withdrawal threshold
was calculated as described previously [16].
Sucrose preference test
As described previously [16], animals were acclimated to
the test room for at least 20 min. Two bottles (1 % sucrose
solution vs. water) were presented to each animal for 1 h.
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At the end of each test, sucrose preference was calculated
as volume of sucrose consumed divided by total liquid
consumption for each rat. Rats were allowed to eat ad
libitum prior the test.
Subcellular fractionation and Western blotting
Rats were anesthetized with Isoflurane (1.5-2 %) and decap-
itated immediately. Brains were quickly removed and NAcs
were collected on ice. The NAcs were dissected from 1.08
to 2.52 mm anterior to Bregma, with average sample weight
of 40 mg. Synaptosome fractions were prepared as de-
scribed previously [89, 90]. To prepare synaptoneurosome
fractions, nucleus accumbens samples were homogenized
in an ice-cold solution A (0.32 M sucrose, 1 mM NaHCO3,
1 mM MgCl2, 0.5 mM CaCl2, 0.1 mM PMSF and 1x
Complete Protease Inhibitors; Roche Applied Science). Ho-
mogenates were centrifuged at 4,000 rpm for 10 min. The
supernatant was collected and the pellet rehomogenized in
solution A and centrifuged again at 3,000 rpm for 10 min.
Combined supernatants were subjected to a second centri-
fugation at 3,000 rpm for 10 min. Supernatants were then
spun at 14,000 rpm for 30 min. Pellet was resuspended in
solution B (0.32 M sucrose, 1 mM NaHCO3) and homoge-
nized. Homogenate was layered on top of a 5 mL 1 M su-
crose and 1.2 M sucrose gradient and centrifuged at
30,000 rpm for 2 h. Purified synaptosomes were collected
at the 1 M and 1.2 M sucrose interface, suspended in solu-
tion B and centrifuged at 40,000 rpm for 45 min. Synapto-
somal pellets were resuspended in 25 mM TRIS with 4 %
SDS. Equal amounts of fractions were loaded on SDS-
PAGE gels and analyzed by Western blot as previously de-
scribed previously [89, 90]. The following antibodies were
used: GluA1 (1:1000, Millipore), phospho-Ser845GluA1
(1:1000, Millipore), GluA2 (1:1000, Millipore) and tubulin
(1:30,000, Sigma-Aldrich).
Electrophysiology
Rats were deeply anesthetized with isofluorane (2 %) and
decapitated immediately. Brains were quickly removed into
dissection buffer consisted of the following (in mM): 75
sucrose, 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7
MgCl2 6 H2O, 25 NaHCO3, 10 dextrose, bubbled with
95 % O2/5 % CO2 (pH 7.4). Coronal slices (300 μm
thick) containing the NAc were cut in ice-cold dissection
buffer using a vibrotome (Leica, VT1200S). The slices
were then transferred to an incubation chamber contain-
ing warm dissection buffer for <30mins, and then moved
into a warm ACSF (ACSF, in mM: 124 NaCl, 2.5 KCl, 1.25
NaH2PO4, 2.5 CaCl2, 1.5 MgSO4 7H2O, 26 NaHCO3, and
10 dextrose) solution and allowed to return to room
temperature for at least 1 h to allow for recovery. Slices
were transferred to the recording chamber and perfused
(2.0–2.5 ml min − 1) with oxygenated ACSF at 33-35 °C
containing 25 μm APV and 10 μm picrotoxin to isolate
EPSCs. Somatic whole-cell recordings were made from
NAc core region medium spiny neurons in voltage-clamp
with a Multiclamp 700B amplifier (Molecular Devices)
using IR-DIC video microscopy. Patch pipettes (4–6 MΩ)
were filled with intracellular solution (in mM: 125 Cs-
gluconate, 2 CsCl, 5 TEA-Cl, 4 Mg-ATP, 0.3 GTP, 10
phosphocreatine, 10 HEPES, 0.5 EGTA, 100 μM spermine,
and 3.5 QX-314). Data were filtered at 2 kHz, digitized at
10 kHz, and analyzed with Clampfit 10 (Molecular De-
vices). Extracellular stimulation (0.01-1 ms, 5–150 μA)
was applied with a small glass bipolar electrode 0.05-
0.5 mm from the recording electrode. EPSC amplitude
was measured at holding potentials of −70, −50, −30,
0, +20, +40 and +60 mV. The rectification index (ir)
was calculated by correcting any potential shifts in re-
versal potential and computed from the following
equation: ir = (I−70/ 70)/(I+40 / 40), where I-70 and I +
40 are the EPSC amplitudes recorded at −70 mV and
+40 mV, respectively [45].
Data analysis and statistics
Two-way ANOVA with repeated measures, followed by
post hoc multiple pair-wise comparison Bonferroni test
was used to compare the 50 % withdrawal threshold of
PI vs. control rats; CFA vs. saline-treated rats and SNI
vs. sham rats. SPT was also analyzed using the two-way
ANOVA test with repeated measures and post hoc mul-
tiple pair-wise comparison Bonferroni test. For total
fluid consumption, sucrose consumption and water con-
sumption on the SPT, an unpaired two-tailed Student’s
t-test was used to analyze performances of PI vs. control
group; CFA vs. saline-treated group and SNI vs. sham
group. For Western blots, two-way ANOVA with post
hoc multiple pair-wise comparison Bonferroni test was
also used to compare the proteins levels of GluA1 and
GluA2 in PI vs. control animals; CFA vs. saline-treated
animals and SNI vs. sham animals. An unpaired two-
tailed Student’s t-test was used to analyze the level of
phospho-Ser845GluA1 in CFA vs. saline and SNI vs.
sham rats. For electrophysiology experiments, difference
in rectification index between CFA and control group
was analyzed using unpaired two-tailed Student’s t-test.
An unpaired two-tailed Student’s t-test was used to com-
pare results on the SPT between Naspm and saline
treatment in PI- and CFA-treated rats. For all tests, a p
value <0.05 was considered statistically significant. All
data were analyzed using GraphPad Prism Version 6
software (GraphPad, La Jolla, CA).
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